1426828-75-2

Upstream product

• 1202021-21-3 (R)-2-[(S,E)-3-(4-methoxybenzyloxy)-7-(tritylthio)hept-4-enamido]-3-methylbutanoic acid 
• 1075206-51-7 (3S,4R)-allyl 4-[(S)-2-amino-3-(tritylthio)propanamido]-3-(tert-butyldimethylsiloxy)-5-methylhexanoate 

Downstream Products

• 1426828-76-3 (3S,4R)-allyl 3-(tert-butyldimethylsiloxy)-4-{(S)-2-[(R)-2-[(S,E)-3-hydroxy-7-(tritylthio)hept-4-enoylamino]isovaleroylamino]-3-tritylthio(propionylamino)}-5-methylhexanate 

Relevant academic research and scientific papers

Total synthesis of bicyclic depsipeptides spiruchostatins C and D and investigation of their histone deacetylase inhibitory and antiproliferative activities

The bicyclic depsipeptide histone deacetylase (HDAC) inhibitors spiruchostatins C and D were synthesized for the first time in a highly convergent and unified manner. The method features the amide coupling of a d-leucine-d-cysteine- or d-valine-d-cysteine-containing segment with a d-alanine- or d-valine-containing segment to directly assemble the corresponding seco-acids, key precursors of macrolactonization. The HDAC inhibitory assay and cell-growth inhibition analysis of the synthesized depsipeptides determined the order of potency of spiruchostatins A-D in comparison with the clinically approved depsipeptide FK228 (romidepsin). Novel aspects of structure-activity relationships (SAR) were revealed.